UCB SA (UCB) - Total Assets

Latest as of June 2026: €20.63 Billion EUR ≈ $24.12 Billion USD

Based on the latest financial reports, UCB SA (UCB) holds total assets worth €20.63 Billion EUR (≈ $24.12 Billion USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

UCB SA - Total Assets Trend (2000–2025)

This chart illustrates how UCB SA's total assets have evolved over time, based on quarterly financial data. Also see UCB SA (UCB) market capitalisation for the company's overall valuation and market capitalisation.

UCB SA - Asset Composition Analysis

Current Asset Composition (December 2025)

UCB SA's total assets of €20.63 Billion consist of 33.3% current assets and 66.7% non-current assets. Review total liabilities of UCB SA to assess the company's total debt and financial obligations.

Asset Category	Amount (EUR)	% of Total Assets
Cash & Equivalents	€0.00	12.4%
Accounts Receivable	€1.79 Billion	9.8%
Inventory	€1.50 Billion	8.2%
Property, Plant & Equipment	€0.00	0.0%
Intangible Assets	€3.45 Billion	19.0%
Goodwill	€5.09 Billion	28.0%

Asset Composition Trend (2000–2025)

This chart illustrates how UCB SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest UCB SA stock price today for real-time trading data and today's change.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: UCB SA's current assets represent 33.3% of total assets in 2025, an increase from 0.0% in 2000.
Cash Position: Cash and equivalents constituted 12.4% of total assets in 2025, up from 4.7% in 2000.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 46.0% of total assets, an increase from 4.0% in 2000.
Asset Diversification: The largest asset category is goodwill at 28.0% of total assets.

UCB SA Competitors by Total Assets

Key competitors of UCB SA based on total assets are shown below.

Company	Country	Total Assets
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	USA	$2.19 Billion
Halozyme Therapeutics Inc NASDAQ:HALO	USA	$2.22 Billion
Revolution Medicines Inc NASDAQ:RVMD	USA	$4.32 Billion
Abivax SA PA:ABVX	France	€584.34 Million
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	China	CN¥8.59 Billion
Beijing Tiantan Biological Products Corp Ltd SHG:600161	China	CN¥16.55 Billion
SOLENO THERAPEUT. DL-001 F:6XC	Germany	€563.83 Million
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	China	CN¥6.66 Billion

UCB SA - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	1.20	1.35	1.23
Quick Ratio	0.82	1.01	0.86
Cash Ratio	0.00	0.00	0.00
Working Capital	€923.00 Million	€1.39 Billion	€555.00 Million

UCB SA - Advanced Valuation Insights

This section examines the relationship between UCB SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	3.65
Latest Market Cap to Assets Ratio	2.34
Asset Growth Rate (YoY)	4.7%
Total Assets	€18.16 Billion
Market Capitalization	$42.54 Billion USD

Valuation Analysis

Premium Asset Valuation: The market values UCB SA's assets at a significant premium (2.34x), suggesting investors see substantial growth potential or unique competitive advantages.

Positive Asset Growth: UCB SA's assets grew by 4.7% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for UCB SA (2000–2025)

The table below shows the annual total assets of UCB SA from 2000 to 2025.

Year	Total Assets	Change
2025-12-31	€18.16 Billion ≈ $21.23 Billion	+4.68%
2024-12-31	€17.35 Billion ≈ $20.28 Billion	+11.64%
2023-12-31	€15.54 Billion ≈ $18.17 Billion	-2.07%
2022-12-31	€15.87 Billion ≈ $18.55 Billion	+11.67%
2021-12-31	€14.21 Billion ≈ $16.61 Billion	+6.69%
2020-12-31	€13.32 Billion ≈ $15.57 Billion	+20.20%
2019-12-31	€11.08 Billion ≈ $12.95 Billion	+5.39%
2018-12-31	€10.51 Billion ≈ $12.29 Billion	+6.02%
2017-12-31	€9.92 Billion ≈ $11.59 Billion	-2.89%
2016-12-31	€10.21 Billion ≈ $11.94 Billion	-6.79%
2015-12-31	€10.96 Billion ≈ $12.81 Billion	+7.96%
2014-12-31	€10.15 Billion ≈ $11.86 Billion	+3.98%
2013-12-31	€9.76 Billion ≈ $11.41 Billion	+4.27%
2012-12-31	€9.36 Billion ≈ $10.94 Billion	+1.98%
2011-12-31	€9.18 Billion ≈ $10.73 Billion	+2.33%
2010-12-31	€8.97 Billion ≈ $10.49 Billion	-1.66%
2009-12-31	€9.12 Billion ≈ $10.66 Billion	-4.24%
2008-12-31	€9.52 Billion ≈ $11.13 Billion	-0.32%
2007-12-31	€9.55 Billion ≈ $11.17 Billion	-8.98%
2006-12-31	€10.50 Billion ≈ $12.27 Billion	+122.56%
2005-12-31	€4.72 Billion ≈ $5.51 Billion	-12.22%
2004-12-31	€5.37 Billion ≈ $6.28 Billion	+73.85%
2003-12-31	€3.09 Billion ≈ $3.61 Billion	+17.93%
2002-12-31	€2.62 Billion ≈ $3.06 Billion	+2.23%
2001-12-31	€2.56 Billion ≈ $3.00 Billion	+11.32%
2000-12-31	€2.30 Billion ≈ $2.69 Billion	--

About UCB SA

BR:UCB Belgium Biotechnology

Market Cap

$46.88 Billion

€40.10 Billion EUR

Market Cap Rank

#646 Global

#4 in Belgium

Share Price

€210.30

Change (1 day)

-0.14%

52-Week Range

€196.50 - €285.40

All Time High

€285.40